FDA Approves Suzetrigine, First Non-Opioid Painkiller in Decades

FDA approves suzetrigine, a non-opioid painkiller that blocks sodium channels, offering potent relief without addiction risks.

FDA Approves Suzetrigine, First Non-Opioid Painkiller in Decades

Photo Credit: Pixabay/Myriams-Fotos

The FDA approved suzetrigine for short-term pain management.

Highlights
  • FDA approves suzetrigine for short-term pain relief
  • Offers opioid-level pain relief without addiction risks
  • First new painkiller mechanism approved in 20+ years
Advertisement

The United States Food and Drug Administration (FDA) has approved suzetrigine, a non-opioid painkiller, for short-term pain management. This approval marks the first time in over two decades that a new pain relief mechanism has been introduced. Suzetrigine, which selectively targets sodium channels on pain-sensing neurons, has been developed as an alternative to opioids, which have been linked to addiction and overdose crises. The drug is expected to provide pain relief similar to opioids but without the associated risks of dependency, sedation, or overdose.

Targeting Sodium Channels for Pain Relief

According to research presented at a major anesthesiology conference last year, suzetrigine, now branded as Journavx, works by blocking the NaV1.8 sodium channel subtype, which plays a key role in transmitting pain signals. Unlike traditional sodium channel-blocking drugs like lidocaine, which act on all nine subtypes indiscriminately, suzetrigine is designed to target pain-sensing neurons specifically. This selectivity reduces side effects and allows the drug to be taken orally rather than requiring local application.

Clinical Trials and Effectiveness

In clinical trials, more than 80% of participants reported effective pain relief after surgery or injury. Trials on individuals undergoing procedures such as bunion removal and tummy tucks showed that suzetrigine provided pain relief comparable to opioid-based regimens, with fewer side effects. Paul White, an anesthesiologist at Cedars-Sinai Medical Center, stated to Nature, that increasing non-opioid options could significantly reduce opioid dependency.

Challenges and Future Prospects

Suzetrigine has been priced at $15.50 per pill, a cost that remains higher than generic opioids but is considered cost-effective given the expenses associated with opioid addiction treatment. While its effectiveness in chronic pain conditions remains uncertain, pharmaceutical companies are advancing similar drugs targeting sodium channels, aiming to expand non-opioid pain relief options.

 

Comments

For the latest tech news and reviews, follow Gadgets 360 on X, Facebook, WhatsApp, Threads and Google News. For the latest videos on gadgets and tech, subscribe to our YouTube channel. If you want to know everything about top influencers, follow our in-house Who'sThat360 on Instagram and YouTube.

Gadgets 360 Staff
The resident bot. If you email me, a human will respond. More
Apple Said to Stop Development of AR Glasses for Mac Computers
Budget 2025: Tech in Focus With Framework for GCCs, New 'Fund of Funds' for startups, CoE for AI
Facebook Gadgets360 Twitter Share Tweet Snapchat LinkedIn Reddit Comment google-newsGoogle News

Advertisement

Follow Us
© Copyright Red Pixels Ventures Limited 2025. All rights reserved.
Trending Products »
Latest Tech News »